January 31, 2020 / 12:10 PM / 2 months ago

BRIEF-Roche Receives Positive CHMP Opinion For Lymphocytic Leukaemia Drug

Jan 31 (Reuters) - Roche Holding AG:

* ROCHE ANNOUNCES CHMP RECOMMENDATION FOR EU APPROVAL OF VENCLYXTO PLUS GAZYVARO FOR PEOPLE WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKAEMIA

* POSITIVE CHMP RECOMMENDATION BASED ON PIVOTAL PHASE III CLL14 STUDY SHOWING THAT FIXED DURATION OF TREATMENT WITH VENCLYXTO PLUS GAZYVARO REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 65% COMPARED TO CURRENT STANDARD-OF-CARE

* VENCLYXTO IN COMBINATION WITH GAZYVARO REPRESENTS A POTENTIAL NEW, FIXED 12-MONTH, CHEMOTHERAPY-FREE OPTION FOR PEOPLE WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKAEMIA Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below